Axsome Therapeutics has received the US Food and Drug Administration (FDA) approval for Auvelity (dextromethorphan HBr and ...
At WIRED Health, pioneering Alzheimer's researcher John Hardy outlined the stakes—and next steps—of where treatment is headed ...
The Alzheimer's Association, Arkansas Chapter and the University of Arkansas for Medical Sciences' Donald W. Reynolds ...
Diet, gut health, cardiovascular conditions and surgical history were identified as the most prevalent drivers of Alzheimer’s ...
GSK and Alector have stopped a phase 2 trial of their Alzheimer’s disease drug candidate after an interim analysis found the ...
The FDA expanded the indication for dextromethorphan hydrobromide and bupropion hydrochloride (Auvelity) extended-release ...
The FDA has approved Auvelity for treating agitation in patients with dementia due to Alzheimer’s disease, Axsome ...
L-arginine helps protein droplets stay stable and prevents fibril formation linked to Alzheimer’s. This process occurs at droplet surfaces, offering a potential therapeutic target.
AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to ...
Four years after gaining FDA approval for Auvelity to treat major depressive disorder (MDD), Axsome Therapeutics has tacked ...
By Kamal Choudhury and Mariam Sunny April 30 (Reuters) - The U.S. Food and Drug Administration has approved Axsome ...
The idea is straightforward: Take a blood test now, even without symptoms, and learn if you could some day develop ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results